YanLev / Shutterstock.com
Following the Federal Circuit’s ruling in Amgen v Sandoz, biosimilar applicants should weigh up several factors when deciding whether to opt into the so-called patent dance. Gerard Norton and Michael Montgomery of Fox Rothschild discuss the potential strategies.
The Biologics Price Competition and Innovation Act (BPCIA) is a landmark piece of legislation signed into law by the Obama administration in 2009. The BPCIA provides for a regulatory approval pathway for biosimilar products, which are like generic pharmaceuticals in that they are based on already approved ‘name brand’ biologics.
Until this year, the Food and Drug Administration (FDA) had not approved any biosimilar applications. The first biosimilar application to be approved was Sandoz’s Zarxio in March. When Sandoz filed its biosimilar application with the FDA, it indicated that Zarxio was a biosimilar version of Amgen’s Neupogen (filgrastim).
Amgen was designated as the reference product sponsor (RPS), and under the BPCIA Sandoz was supposed to provide Amgen with a copy of Sandoz’s submission to the FDA. Sandoz instead decided against providing a copy to Amgen, but did provide a 180-day advance notice of commercial marketing to Amgen. Both actions by Sandoz became the subject matter of the underlying dispute in Amgen v Sandoz, which the US Court of Appeals for the Federal Circuit resolved on July 21, 2015.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Gerard Norton, Michael Montgomery, Fox Rothschild, FDA, Amgen v Sandoz, patent, BPCIA, biosimilars, RPS,